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Background: Advanced or metastatic renal cell carcinoma (RCC) has a poor prognosis, because it is relatively
resistant to conventional chemotherapy or radiotherapy. Treatments with human interferon-α2b alone or in
combination with mammalian target of rapamycin (mTOR) inhibitors have led to only a modest improvement in
clinical outcome. One observation made with mTOR inhibitors is that carcinomas can overcome these inhibitory
effects by activating the insulin-like growth factor-I (IGF-I) signaling pathway. Clinically, there is an association of
IGF-I receptor (IGF-IR) expression in RCC and poor long-term patient survival. We have developed a humanized anti-
IGF-IR monoclonal antibody, hR1, which binds to RCC, resulting in effective down-regulation of IGF-IR and
moderate inhibition of cell proliferation in vitro. In this work, we evaluate the anti-tumor activity of two novel IGF-1R
-targeting agents against renal cell carcinoma given alone or in combination with an mTOR inhibitor.
Methods: hR1 was linked by the DOCK-AND-LOCK™ (DNL™) method to four Fabs of hR1, generating Hex-hR1,
or to four molecules of interferon-α2b, generating 1R-2b. Eight human RCC cell lines were screened for IGF-1R
expression and sensitivity to treatment with hR1 in vitro. Synergy with an mTOR inhibitor, temsirolimus, was tested
in a cell line (ACHN) with low sensitivity to hR1.
Results: Hex-hR1 induced the down-regulation of IGF-IR at 10-fold lower concentrations compared to the parental
hR1. Sensitivity to growth inhibition mediated by hR1 and Hex-hR1 treatments correlated with IGF-1R expression
(higher expression was more sensitive). The potency of 1R-2b to inhibit the in vitro growth of RCC was also
demonstrated in two human cell lines, ACHN and 786-O, with EC50–values of 63 and 48 pM, respectively. When
combined with temsirolimus, a synergistic growth-inhibition with hR1, Hex-hR1, and 1R-2b was observed in ACHN
cells at concentrations as low as 10 nM for hR1, 1 nM for Hex-hR1, and 2.6 nM for 1R-2b.
Conclusions: Both Hex-hR1 and 1R-2b proved to be more potent than parental hR1 in inhibiting growth of RCC in vitro.
Synergy was achieved when each of the three hR1-based agents was combined with temsirolimus, suggesting a new
approach for treating RCC.
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In the United States, renal cell carcinoma (RCC) is the
seventh and ninth most common form of cancer in men
and women, respectively, and a recent report estimates
that in 2012, 40,250 men and 24,520 women will be
diagnosed with, and 13,570 will die of, this disease [1].
The therapeutic options for RCC have increased consi-
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reproduction in any medium, provided the oragents [2,3] developed to interrupt the molecular path-
ways regulating tumor angiogenesis, cell proliferation,
and survival. Treatments of metastatic RCC with these
agents, which are inhibitors of vascular endothelial
growth factor (VEGF) (bevacizumab), VEGF-receptors
(VEGFR) (sorafenib, sunitinib, pazopanib, and axitinib),
or mTOR (temsirolimus and everolimus), have a signifi-
cantly improved survival, but remain palliative. Thus, a
cure for metastatic RCC continues to be elusive, but is
being pursued actively with various combination strat-
egies. In this respect, it is noted that the time-honored,
but not regulatory-approved, therapies with interferon-l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in combination with some of these agents. For example,
IFN-α2b combined with sorafenib achieved an overall
response rate of 33% in patients with metastatic disease
[4]; IFN-α2b combined with temsirolimus was not as ef-
fective as temsirolimus alone [5]; and IFN-α combined
with bevacizumab significantly increased progression-
free survival and objective responses [6]. One major
challenge with IFN-α therapy, either alone or in combin-
ation, is the frequency with which IFN-α needs to be
administered (6 to 10 ×106 U three times weekly).
Another problem associated with IFN-α therapy was the
adverse events, which include fatigue, fever, nausea, flu-like
symptoms, and anorexia [4,6]. While pegylated IFN-α has
allowed for less frequent dosing, many of the same toxic
effects remain without appreciable improvement in patient
outcome [7,8].
Inhibition of the mTOR kinase results in the reduction of
regulatory proteins involved in the progression of cells from
the G1 to S-phase of their growth cycle [9]. However,
blocking mTOR activity with rapamycin (the prototype
mTOR inhibitor) or rapamycin analogs inadvertently acti-
vates the Akt-signaling pathway [9] through an IGF-1R
-dependent mechanism [10], which mitigates the anti-
tumor effects of the mTOR inhibitors. Thus, the combin-
ation of an anti-IGF-IR antibody with mTOR inhibitors
was shown to block the Akt-signaling pathway in rhabdo-
myosarcoma, breast, and prostate carcinomas, resulting in
an additive increase in cell growth-inhibition [9,10].
IGF-1R-targeted therapy in RCC was implicated by an
early finding of a greater than 10-fold reduction in tumor
growth in mice bearing xenografts of human clear-cell
RCC when administered with an antagonist to growth
hormone-releasing hormone, which was attributed to a re-
duction of IGF-1 [11]. Analysis of RCC tissue specimens
showed the expression of both IGF-1 and IGF-IR in clear-
cell-RCC, papillary-RCC, and chromophobe RCC [12].
Overall, an association of IGF-1R expression and poor
long-term patient survival was found, particularly among
patients with high-grade tumors [13]. Mutations in the
von Hippel-Lindau (VHL) gene have been linked to
hereditary kidney cancer and in 70% of non-hereditary
clear-cell-RCC [14]. It was shown that the wild type VHL
encodes a 30-kDa protein that inhibits RCC metastasis
and IGF-IR to form complexes with PKCδ, a protein
kinase linked to cell proliferation and transformation
[15].
We have developed a humanized anti-IGF-1R anti-
body, hR1, which binds to IGF-1R without blocking
binding of IGF-1 or IGF-2 to the receptor, yet effectively
causes receptor down-regulation, and inhibits cell prolif-
eration, colony formation, and cell invasion in a variety
of cancer types, including breast, prostate, cervical,
pancreatic, and rhabdomyosarcoma [16]. Additionally,using the DOCK-AND–LOCK™ (DNL™) platform tech-
nology [17,18], a hexavalent form of hR1 (Hex-hR1) was
engineered in which four hR1 Fabs were linked to hR1 IgG
[16]. Hex-hR1 and hR1 were found to have similar activity,
although Hex-hR1 was more effective at down-regulating
IGF-1R. Importantly, both hR1 and Hex-hR1 were able to
significantly inhibit the anchorage-independent growth of
two different RCC lines in soft-agar assays. When both hR1
and Hex-hR1 were combined with rapamycin treatment of
mice bearing a human rhabdomyosarcoma, significant
tumor growth inhibition was achieved in comparison to
either agent used alone [16].
This same DNL technology can be utilized to attach
four molecules of IFN-α to hR1. It has already been
demonstrated that by using this method with an anti-CD20
antibody, a significant improvement in therapeutic efficacy
in mice bearing xenografts of human non-Hodgkin
lymphoma is achieved when compared to either the
parental antibody alone or peginterferon alfa-2a [19].
By attaching the IFN-α2b to an antibody that targets
the tumor, the therapeutic window of IFN-α should
improve by concentrating IFN-α at the tumor, while
at the same time decreasing the amount in the blood
and normal tissues, where its toxicity manifests.
The known association of mTOR and IGF-IR signaling
pathways, along with the correlation in IGF-1 and IGF-IR
expression patterns in RCC, provide an attractive rationale
for a combination therapy. Moreover, with current IFN-α
treatments and the added benefit already observed in a
rhabdomyosarcoma tumor model with an anti-IGF-IR anti-
body enhancing the therapeutic effects of mTOR inhibitors
or to specifically target IFN-α to a tumor, there is the
potential to provide a new combination therapy for
metastatic RCC. We report here that a screening of
eight different human RCC cell lines reveals that all
eight express IGF-1R at varying levels. Sensitivity to
IGF-1 stimulation and growth-inhibitory effects of
hR1 or Hex-hR1 are related to this expression. The
hR1-IFN-α2b DNL product, 1R-2b, was found to have
activity similar to recombinant human IFN-α and could
inhibit RCC growth with EC50-values in the picomolar
range. Importantly, there is a strong synergistic effect
when hR1, Hex-hR1, or 1R-2b is combined with the
rapamycin analog, temsirolimus.
Methods
Cell lines, antibodies, and reagents
All cell lines were purchased from American Type Culture
Collection, except CAL-54 and RH-30, which were obtained
from the Deutsche Sammlung von Mikroorganismen und
Zellkulturen. Humanized antibodies, including hR1, hA20
(anti-CD20), hRS7 (anti-Trop-2), and h225 (anti-epidermal
growth factor receptor (EGFR)), were provided by
Immunomedics. Recombinant human IGF-1 and murine
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R&D Systems. Phospho-specific antibodies and other
primary antibodies were acquired from Cell Signaling or
Santa Cruz Biotechnology. Horseradish peroxidase (HRP)-
conjugated secondary antibody and One Solution Cell
Proliferation assay (MTS) were obtained from Promega.
FITC-conjugated secondary antibodies were from Jackson
ImmunoResearch Laboratories. PhosphoSafe Extraction
Reagent and RIPA buffer used for cell lysis were obtained
from EMD Biosciences and Cell Signaling, respectively. Cell
culture media, supplements, and bovine transferrin (holo
form) were purchased from Invitrogen. Temsirolimus
(Wyeth) was purchased from Florida Infusion. Recombinant
human Interferon-α2a (rhIFN-α2a, Millipore), peginterferon
alfa-2b (Schering) and peginterferon alfa-2a (Hoffmann-La
Roche) were purchased. Protein Assay Dye Reagent
Concentrate was from Bio-Rad. All other chemicals were
purchased from Sigma.Cell culture
RCC cell lines 769-P and 786-O were maintained in
RPMI-1640 medium. For CAL-54, A-498, A-704 and
ACHN, Eagle’s MEM medium was used, and for Caki-1
and Caki-2, McCoy’s 5a medium. All three media were
supplemented with 10% heat-inactivated fetal bovine
serum (FBS), 1% GlutaMax, 1% non-essential amino acids,
and 1% sodium pyruvate. Cultures were maintained at
37°C in 5% CO2 and medium changed at least once
weekly. Only cells with fewer than 50 passages were used
for experiments.Generation of Hex-hR1 and 1R-2b by DNL
The preparation of Hex-hR1 has been described [16].
1R-2b was prepared as described for 20-2b [19] by reacting
CH3-AD2-hR1-IgG, instead of CH3-AD2-hA20-IgG, with
IFN-α2b-DDD2. The molecular integrity and product
purity of Hex-hR1 and 1R-2b were determined by
size-exclusion high performance liquid chromatography
(SE-HPLC) on a Beckman System Gold Model 116
with a BioSep-SEC-s3000 column (300 × 7.80 mm) of
Phenomenex using 0.04 M PBS (pH 6.8) plus 1 mM
EDTA as the mobile phase.Surface IGF-1R expression by flow cytometry
Each sample was prepared in duplicate to contain 2×105
cells and 67 nM of a test antibody in a final volume of
200 μL. After incubation at 4°C for 45 min, samples
were washed twice with PBS-1% BSA, followed by the
addition of FITC-GAH IgG, (H + L), and a further incu-
bation at 4°C for 45 min in the dark. Samples were
washed twice with PBS-1% BSA, resuspended in 500 μL
of PBS-buffered formalin, and analyzed on FACScan.Cell proliferation assay
All cell incubations were performed at 37°C in a humidi-
fied 5% CO2 incubator. Cells were detached with trypsin,
washed three times with PBS to remove any trace of serum,
and resuspended in a serum-free medium containing
10 μg/mL of bovine transferrin (SFM-Trf). Cells were
seeded at 1×103 cells/50 μL/well and incubated overnight.
On the following day each test article in SFM-Trf was
5-fold serially diluted from 400 nM to 0.001 nM and
50 μL of each concentration were added in triplicate
to the wells, such that the final concentrations of the
test article ranged from 200 nM to 0.0005 nM.
Untreated control cells received only 50 μL of SFM-Trf.
After incubation for 1 h, designated wells received 100 μL
of each test article at the same concentration in SFM-Trf
containing 50 ng/mL of IGF-1. Plates were then incubated
for a period of time as indicated and cell viability assessed
using the MTS assay as per the manufacturer’s protocol.
Growth inhibition was measured as a percent of growth
relative to untreated cells using Microsoft Excel and Prism
GraphPad Software (v4.03; Advanced Graphics Software,
Inc.). Combinatorial Index (CI) was calculated by median
effect analysis [20,21] to determine synergism (CI < 0.9),
additivity (1.1 > CI > 0.9), or antagonism (CI >1.1).
Immunoblot analysis
Unless otherwise stated, cells were starved in serum-free
medium for 24 h, treated, and lysed at ice-cold temperature
in a buffer as specified. Protein concentrations were deter-
mined by the Bio-Rad Protein Assay and samples (20 μg
loaded in each lane) were separated on 4-20% Tris-Glycine
gels, transferred to PDVF or nitrocellullose membranes,
blocked with TBST buffer (50 mM Tris pH 8.0, 150 mM
NaCl, 0.1% Tween 20) containing 5% nonfat milk, washed
with TBST buffer, and incubated overnight at 4°C with
primary antibodies. The membranes were then washed in
TBST four times (once for 15 min and three more for
5 min each), incubated with HRP-conjugated secondary
antibodies for 1 h at RT, washed in TBST buffer four times
as described above, then detected with Super Signal West
Dura Extended Duration Substrate (Thermo Scientific)
according to the directions provided by the manufac-
turer. The immunoblot signals were visualized with a
chemiluminescence system (Thermo Scientific). Digital
images were processed by Carestream (Carestream
Molecular Imaging).
Down-regulation of IGF-IR
Cells were seeded at 1×106 per well in a 6-well plate and
cultured overnight for attachment. On the next day, the
medium was replaced with fresh media containing a test
article of interest at indicated concentrations and cells
were further incubated as indicated. Treated cells were
washed with cold PBS, scraped from the dishes, collected,
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pellets were lysed for 10 min on ice in RIPA buffer or a
buffer consisting of 25 mM Tris (pH 8), 150 mM NaCl,
1 mM EDTA, 1% Triton and 1 X Complete, EDTA-free
Protease Inhibitor Cocktail (Roche Diagnostics). The
lysates were clarified by centrifugation, assayed for protein
concentration, and analyzed by immunoblotting.
Detection of IGF-1R/IR hybrid
Cells grown in T150 flasks were washed twice with ice-cold
PBS and scraped by adding ice-cold lysis buffer. Lysates
were centrifuged for 15 min at 13,000 × g at 4°C. Superna-
tants were assayed for protein content using the BCA assay
kit. Aliquots of 500 μg of total protein in equal amount of
lysis buffer were pre-cleared with protein A beads (Cell
Signal Technology) for 2 h. The pre-cleared lysate was
incubated overnight at 4°C with anti-IGF1R antibody
(MAB391,1:100, Santa Cruz Biotechnology). Samples were
then incubated with 40 μL of protein A beads for 2 h. The
beads were washed four times with lysis buffer and
collected by centrifugation. Beads were resuspended in 2×
sample buffer and boiled for 5 min. A 20-μL aliquot of the
supernatant was subjected to gel electrophoresis and West-
ern blotting with an anti-insulin receptor-β antibody (anti-
IR-β) to detect heterodimers. As a control for the presence
of IGF-1R in the immunoprecipitated samples, the blots
were also probed with an anti-IGF-1Rβ antibody. IR-β
levels were assessed by running 25 βg from the same lysates
used for immunoprecipitation and probed with anti-IR-β
antibody. Loading control was β-actin.
Determination of IFN activity
Two different assays were utilized to determine the
specific activity of 1R-2b. The first used the luciferase
reporter gene assay (iLite kit; PBL InterferonSource) follo-
wing manufacture’s instructions in which rhIFN-α2a was
used as a standard for activity. A second measure of activity
tested the ability of IFN-α2a to mediate the phosphory-
lation of STAT1, AKT or ERK1/2 in ACHN cells. Briefly,
cells (5 × 105 per well) were grown in 10% FBS medium in
6-well plates overnight for attachment. Medium was
changed and interferon (rhIFN-α2a or 1R-2b) was added at
the indicated concentrations. At indicated times, cell lysates
were prepared and resolved by SDS-PAGE, transferred to
nitrocellulose membranes and probed with appropriate
anti-phospho antibodies (p-STAT1, p-ERK1/2, p-AKT)
or anti-NUB1. Loading controls utilized antibodies to
unphosphorylated proteins (STAT1, ERK1/2, AKT) or
to β–actin (NUB1).
Statistical analysis
Results are shown as means ± standard deviations.
Statistical differences between two values were determinedby Student’s t-test. A value of P < 0.05 was considered
statistically significant.
Results
Characterization of Hex-hR1 and 1R-2b
Hex-hR1 and 1R-2b were analyzed by SE-HPLC, showing
a single peak at 7.47 min (Figure 1A) and a major peak at
7.88 min (Figure 1B), respectively. The smaller peak
observed for 1R-2b at 7.06 min (16% area) is presumably a
dimer of 1R-2b, due to the propensity of interferon to self-
associate [19]. As shown in Figure 1C, both Hex-hR1 and
1R-2b bind to ACHN cells with no appreciable difference
from the parental hR1.
Down-regulation of IGF-1R
Down-regulation of IGF-1R in ACHN cells after exposure
to either Hex-hR1 or hR1 at 66 nM was apparent in
10 min, achieving a nearly complete elimination of IGF-1R
at 6 h (Figure 2A). In ACHN cells, the potency of Hex-hR1
to down-regulate IGF-1R was demonstrable at 0.1 nM, as
compared to that of hR1 at 1 nM (Figure 2B). At 0.1 nM,
the degree to which Hex-hR1 was able to down-regulate
IGF-1R was significantly higher than that of the parental
hR1 (Figure 2C; P = 0.031).
Surface IGF-1R expression, formation of IGF-1R/IR hybrid,
and sensitivity to anti-IGF-1R treatment
IGF-1R expression levels on the cell surface were deter-
mined across a panel of eight different human RCC cell
lines by hR1 staining via FACS analysis (Table 1). All cell
lines tested were moderately to weakly positive for
hR1 binding, with a range of reactivity from the
highest for Caki-2 to the lowest for A-704. When
compared to EGFR expression, in all cases the surface
expression level of EGFR was much higher than IGF-1R
in a given cell line.
Heterodimerization of IGF-1R and insulin receptor
(IR) has been linked to sensitivity to anti-IGF-1R anti-
bodies [22]. To determine if such hybrid receptors are
generally formed in RCC, all eight RCC cell lines were
analyzed for the presence of IGF-1R/IR heterodimers
(Figure 2D). Five of the eight cell lines demonstrated little
or no presence of hybrid formation. Of these five, one
(A498) had little expression of IGF-1R, two (ACHN and
786–0) had no detectable levels of IR, and the remaining
two (Caki-2 and 769-P) expressed both receptors but did
not show hybrid formation. Of the eight cell lines tested
only three, A-704, Caki-1 and CAL-54, demonstrated the
presence of IGF-1R/IR heterodimers, suggesting that IR
may not play a key role in IGF-1-mediated growth stimula-
tion of RCC.
It has also been proposed that a cell line’s growth re-
sponse to IGF-1 stimulation is predictive of its sensitivity
to an anti-IGF-1R antibody [23]. In order to gauge
Figure 1 (See legend on next page.)
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Figure 1 Characterization of Hex-hR1 and 1R-2b. A 50-μg sample of (A) Hex-hR1 or (B) 1R-2b was run on SE-HPLC as described in Materials
and Methods. Histograms show UV absorbance of eluted material versus time. (C) Cell binding of hR1, Hex-hR1, and 1R-2b at equimolar
concentrations on ACHN cells by FACS staining. Anti-CD20 antibody, hA20, served as negative control.
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IGF-1R treatment, cells were grown in SFM-Trf
supplemented with human IGF-1 (20 ng/mL). Their abil-
ity to grow relative to control cells (incubated in serum-
free medium only) was measured after 4 days in culture
(Figure 3A), which showed several of the cell lines had a
greater than 20% increase in growth. Overall, stimulation
by IGF-1 followed the expression levels of IGF-1R, in that
Caki-2 was the best responder (74% stimulation) and had
the highest expression, while A-498 had one of the lowest
expression levels and was unresponsive.
Based on the IGF-1 stimulatory effects, three RCC lines
(Caki-2, ACHN, and 786-O) were selected for further test-
ing for anti-IGF-1R-mediated growth-inhibition (Figure 3B).
Consistent with the IGF-1 stimulation results, hR1
had less of an effect on inhibiting the growth of
ACHN cells (10.6 ± 2.6%) when compared to Caki-2
and 786-O cells (33.3 ± 0.6% and 25.9 ± 5.4%, respectively;
P < 0.01 vs. ACHN). Conversely, Hex-hR1 could inhibit
growth by greater than 35% in all three cell lines, with the
greatest effect in Caki-2 (43%) and ACHN (48%). In both
these cell lines, this inhibition was greater than that
observed with the parental hR1 antibody (P < 0.0001).
Interestingly, control antibody MAB391 had similar activ-
ity as the Hex-hR1 in these cell lines. It should be noted
that the mechanism of action for MAB391 is to block
IGF-1 binding to IGF-1R [24], while Hex-hR1 down-
regulates the receptor, suggesting that in these cell lines,
down-regulation of the receptor with Hex-hR1 was as ef-
fective as blocking IGF-1 from binding to the receptor in
inhibiting cell growth.
In vitro potency of 1R-2b
Based on the luciferase reporter gene assay, the specific
activity of 1R-2b was measured at 3750 U/pmol, which
was considerably higher than peginterferon alfa-2a (180
U/pmol) and comparable to peginterferon alfa-2b (3255
U/pmol). These results are consistent with findings of
other MAb-IFN agents made with the DNL method-
ology [19]. A further confirmation of activity was dem-
onstrated by its ability to mediate phosphorylation of
STAT1, ERK1/2 and AKT in ACHN cells (Figure 4A).
When normalized to untreated control levels, both 1R-2b
and rhIFN-α2a mediated a greater than 65-fold increase in
p-STAT1 levels at the highest dose examined (100 U/mL).
This increase in p-STAT1 levels was dose-dependent for
both agents. At the intermediate doses of 10 and 1 U/mL,
p-STAT1 levels were approximately 20- and 2-fold
greater than control levels, respectively. The actualprotein concentrations for 1R-2b and rhIFN-α2a to achieve
STAT1 phosphorylation were found to be similar. For
example, at 10 U/mL the amounts of 1R-2b and rhIFN-α2a
were 2.7 and 2.4 pM, respectively. While both ERK1/2 and
AKT were constitutively phosphorylated in untreated
cells, 1R-2b mediated an approximate 2-fold increase
in p-ERK1/2 and p-AKT levels at the highest dose
tested of 100 U/mL, which was similar to the effects
mediated by rhIFN-α2a.
Another important molecule linked to the growth-
inhibitory effects of IFN in RCC is NUB1 [25]. This
molecule was shown to be up-regulated by IFN in RCC cell
lines, which in turn had a positive correlation with growth
inhibition. The two cell lines reported to show the greatest
up-regulation were ACHN and 786-O, and therefore these
two were chosen to determine the effect of 1R-2b on
NUB1expression (Figure 4B). Similar to what was reported
with rhIFN in these two cell lines, 786-O demonstrated a
greater than 2-fold up-regulation of NUB1, while
ACHN had only a modest 1.2-fold increase. Likewise,
when 786-O cells were incubated with 1R-2b, there was a
greater than 2-fold increase in NUB1 expression that was
similar to the up-regulation mediated by rhIFN-α2a. Inter-
estingly, exposure of ACHN to 1R-2b resulted in a greater
than 2-fold increase in expression, suggesting that 1R-2b
may have a greater growth-inhibitory effect in ACHN than
one might expect for rhIFN-α2a.
Growth-inhibitory effects of 1R-2b were examined in
ACHN and 786-O cells cultured in medium containing
10% FBS (Figure 4C). In both cells, potent EC50 values
in the picomolar range were observed for 1R-2b (63 and
48 pM in ACHN and 786-O, respectively), which
were largely comparable to those of rhIFN-α2a (75 and 13
pM in ACHN and 786-O, respectively). At the maximum
concentration tested (26 nM, 100,000 U/mL), 1R-2b
inhibited cell growth in ACHN cells by 50.2 ± 0.5%, which
was significantly better than that achieved with rhIFN-α2a
at 41.9 ± 2.5% for (P < 0.005). There were no signifi-
cant differences noted in the 786-O cells (27.6 ± 5.6%
vs. 25.6 ± 3.5%, respectively). These data correlate with
the 1R-2b-mediated up-regulation of NUB1 expression
relative to rhIFN-α2a, in that 1R-2b had a greater inhibi-
tory effect in ACHN relative to rhIFN-α2a, whereas there
was no difference in 786-O.
Synergistic Interactions of hR1, Hex-hR1, and 1R-2b with
an mTOR Inhibitor
Given the known link between signaling events mediated
by IGF-1R and the mTOR pathway, the growth-inhibitory
Figure 2 (See legend on next page.)
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Figure 2 IGF-1R expression. (A) ACHN cells were plated overnight in 6-well plates as described in Materials and Methods. Cells were than
exposed to hR1, Hex-hR1, or control hRS7 antibodies before being lysed and 20 μg protein from these lysates subjected to SDS-PAGE (4-20%)
followed by blotting with an anti-IGF-1Rβ antibody. IGF-1R time-course down-regulation after exposure to constant amount of either hR1 or Hex-
hR1. (B) Cells were exposed to indicated amounts of hR1, Hex-hR1, or hRS7 (anti-Trop-2 antibody) for 6 h before being lysed for Western blotting.
β-actin served at the loading control. Blot shown is representative of three repeat experiments. (C) Ratio of IGF-1R to β-actin loading control
normalized to untreated cells for the various doses of hR1, Hex-hR1 or control hRS7. Data are shown as mean ± standard deviation. Significance
set at P < 0.05 for paired t-test of three experiments. (D) Indicated cells were lysed subjected to immunoprecipitation to determine IGF-1R/IR
hybrid receptors, as described in Materials and Methods. A 20-μL aliquot from each immounoprecipitation preparation was subjected to gel
eletrophoresis and Western blotting. Hep G2 served as the positive control cell line in these experiments [22]. Blot shown is representative of two
repeat experiments. To confirm presence of IGF-1R in IP samples, IP blots were probed with anti-IGF-1R antibody. Additionally, cell lysates were
subjected to Western analysis and probed with an anti-IRβ antibody to show relative levels of IR in the various cell lines. β-actin served at the
loading control.
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the mTOR inhibitor, temsirolimus, were examined in vitro
using ACHN as the target cell line (Figure 5). Based
on a dose–response curve, the IC50 of temsirolimus
in ACHN was 7.76 nM, which dropped to below 2.9 nM
when combined with various concentrations of hR1 (100,
10, or 1 nM), indicating synergy (CI = 0.64). An even
greater synergistic effect (CI = 0.43) was observed when
Hex-hR1 was combined with temsirolimus (Figure 5B).
At the two highest concentrations (100 and 10 nM),
Hex-hR1 improved the IC50 by >130-fold to less than 0.06
nM. As an example of this combined effect, Hex-hR1 at 10
nM inhibited cell growth by 1.8 ± 6.2% and temsirolimus
at its lowest concentration of 0.06 nM by 23.2 ± 4.3%.
However, when the two were incubated together, cell
growth was inhibited by 48.1 ± 1.2%. (P < 0.0007 versus
either agent alone).
Since 1R-2b is effective at levels lower than hR1 or
Hex-hR1, cells were incubated at concentrations of 26,
2.6, or 0.26 nM (Figure 5C). These concentrations are
equivalent to 100,000 to 1000 U/mL of IFN activity. Of
all three agents tested, 1R-2b had the greatest synergistic
effect when combined with temsirolimus (C.I. = 0.02).
At the two higher doses of 26 and 2.6 nM, the IC50
for temsirolimus improved to less than 0.06 nM. As
an indication of this interaction, 1R-2b alone at 2.6
nM (10,000 U/mL) inhibited cell growth by 14.0 ±
8.7%; when combined with 0.06 nM temsirolimus
(23.2 ± 4.3%), this improved to 56.8 ± 9.3% (P < 0.005
versus either agent alone). Overall, both Hex-hR1 andTable 1 Surface expression of IGF-1R and EGFR as determined
Antibody Median f
Caki-2 ACHN CAL-54 786
FITC GAH 3 (2) 3 (2) 5 (5) 4 (
hA20* 3 (2) 3 (2) 4 (6) 4 (
hR1 13 (70) 12 (52) 10 (36) 9 (7
h225** 26 (95) 109 (99) 93 (99) 73 (
*Humanized anti-CD20 antibody, veltuzumab.
**Humanized anti-EGFR antibody.1R-2b had a greater effect when combined with
temsirolimus than the parental hR1 antibody, but all
three demonstrated synergy when used in concert
with this mTOR inhibitor.
Discussion
Among kidney cancer types, approximately 90% are
RCC, in which clear-cell-RCC comprises approximately
75% of all cases, and papillary RCC makes up an
additional 15%. Patients present with metastatic disease
30% of the time. Unfortunately, patients with metastatic
RCC have a poor prognosis, since it has remained resistant
to both radiotherapy and chemotherapy [14].
Current treatments for metastatic RCC include IFN-α
[7,8,26], RTK inhibitors, for example, sorafenib, sunitinib,
and temsirolimus [4,5,27], and anti-VEGF receptor anti-
bodies, such as bevacizumab [6]. These agents have been
tested alone and in combinations, with some improvement
in clinical outcomes.
Another approach focuses on IGF-IR as a potential
therapeutic target [11-13,15]. There is evidence of an
autocrine-paracrine loop in RCC growth [12], and
that the expression of IGF-IR and one of its ligands,
IGF-1, has a positive association with poor survival of
patients with high-grade tumors [13]. By blocking
IGF-IR signaling, it was shown pre-clinically that
RCC growth could be reduced significantly [11] and
cell invasiveness inhibited [15]. We have demonstrated
that hR1 binds to multiple tumor types, including RCC
[16]. Additionally, a hexavalent form of hR1 (Hex-hR1)by flow cytometry
luorescence (%Positive)
-O Caki-1 769-P A-704 A-498
6) 4 (4) 3 (4) 7 (2) 3 (4)
6) 4 (4) 3 (4) 7 (2) 3 (4)
1) 8 (21) 8 (21) 10 (5) 5 (21)
98) 22 (76) 79 (98) 97 (92) 100 (98)
Figure 3 In vitro sensitivity to anti-IGF-1R treatment. (A) Various RCC cell lines were plated in 96-well plates overnight in SFM media before
being stimulate with 20 ng/mL of IGF-1. Cells were incubated a further 96 h before cell viability determined as described in Materials and
Methods. Growth relative to cells grown only in SFM are shown in the graph. Large dotted line indicates growth of cells in SFM while smaller
dotted line indicates point of 50% increase in growth. RH30 served as a positive control cell line. (B) In vitro cytotoxicity assay was run as
described in Materials and Methods and compared hR1, Hex-hR1, and positive control MAB391. After 96-h incubation, growth as a percent of
untreated cells is shown in the graphs. The table shows maximum growth-inhibition achieved in the various cell lines with each antibody and
the concentration required to achieve that inhibition. Data are shown as mean ± standard deviation.
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http://www.biomedcentral.com/1471-2407/13/170was created by the DNL™ -platform technology. DNL ex-
plores a pair of distinct protein domains involved in the
natural association between cAMP-dependent protein
kinase (PKA) and A-kinase anchoring proteins (AKAPs),
which can serve as linkers for site-specific conjugation of
an immunoglobulin to either two dimers of IFN-α2b or
four Fab fragments of an immunoglobulin, resulting in
a hexavalent antibody [17-19]. Recently, in a varietyof solid tumor lines, including breast, colon, and
prostate, both hR1 and Hex-hR1 were shown to cause
receptor down-regulation, inhibiting cell growth and
invasiveness. It was noted that Hex-hR1 was much
more effective at receptor down-regulation than the
parental hR1. Additionally, they could both inhibit
colony formation and growth in soft-agar of two
human RCC cell lines [16]. In the present study, hR1
Figure 4 In vitro potency of 1R-2b. (A) IFN-α mediation of phosphorylation of STAT1, ERK1/2 and AKT in ACHN cells was performed as
described in Materials and Methods. Cells were exposed to the indicated amounts of 1R-2b or rhIFN-α2a for 30 min (p-STAT1) or 60 min (p-ERK1/
2 and p-AKT). Fold-increase in phosphorylation was calculated relative to total protein loading controls and normalized to untreated cells. (B)
NUB1 expression was determined as described in Materials and Methods. ACHN or 786-O cells were exposed to 3000 U/mL of 1R-2b or rhIFN-α2a
for 24 h. Up-regulation was determined relative to β-actin loading control and normalized against untreated cells. (C) Growth inhibition was
performed as described in Materials and Methods in complete media containing 10% FBS. A dose/response curve was generated with 1R-2b or
rhIFN-α2a ranging from 1×105 to 0.26 U/mL. Graphs show growth relative to untreated control and represent the mean ± standard deviation.
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http://www.biomedcentral.com/1471-2407/13/170and Hex-hR1 were likewise very effective at mediating
down-regulation of IGF-1R in RCC. Also, as was
noted in other solid tumor lines, Hex-hR1 was more
effective than hR1 at mediating receptor down-
regulation at picomolar concentrations, suggestingthat it may be a more potent anti-tumor agent than
its parental hR1 antibody.
In human breast cancer, of 41 different cell lines tested,
only 7 were sensitive to the growth-inhibitory effects of an
anti-IGF-1R antibody [23]. Two of the main factors cited
Figure 5 Synergistic interaction of temsirolimus with various anti-IGF-1R molecules. Cytotoxicity assays were performed as described in
Materials and Methods. A dose/response curve with temsirolimus was made from 1x10-6 to 6.1x10-11 M. To one set of temsirolimus wells was added a
constant amount of (A) hR1 or (B) Hex-hR1 at 100 nM, 10 nM, or 1 nM. (C) For 1R-2b, a constant amount of 26, 2.6, or 0.26 nM was added to the wells.
After 96 h incubation, growth relative to untreated cells was determined and the amount of temsirolimus required to inhibit cell growth by 50% was
calculated for temsirolimus alone or when used in combination with hR1, Hex-hR1, or 1R-2b. C.I. values were determined as described, with a value less
than 1 indicative of synergy. Dotted lines indicate growth-inhibition of each anti-IGF-1R agent alone. Data are shown as mean ± standard deviation.
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http://www.biomedcentral.com/1471-2407/13/170as predictive for anti-IGF-1R treatment were expression
of IGF-1R and growth-stimulatory effects of IGF-1. In
addition, the presence of IGR-1R and IR-β heterodimers in
hepatic and gastric cell lines has been linked to sensitivity
to anti-IGF-1R antibodies [22]. A panel of eight different
human RCC cell lines was screened by FACS with hR1 for
surface expression of IGF-1R and by Western blotting for
IGF-1R/IR-β hybrid receptors. While all eight expressed
IGF-1R, this expression varied between the cell lines, from
a high in Caki-2 to a low in A-498. Conversely, only three
of the RCC lines expressed the IGF-1R/IR-β heterodimer
(A704, Caki-1 and CAL-54). We found that, like the breastcancer lines, RCC lines varied in their sensitivity to IGF-1
stimulation. Except for ACHN, which had IGF-1R expres-
sion similar to Caki-2, the other cell lines tested fell in the
order of the higher the IGF-1R expression, the greater the
effect of IGF-1 stimulation. Expression of the IGF-1R/IR-β
hybrid receptor did not correlate with increased sensitivity
to IGF-1 stimulation. For example, A-704, which has the
heterodimer, had a lower response to IGF-1 than did
Caki-2, which did not demonstrate the presence of
the hybrid receptor despite expressing both IGF-1R
and IR-β. To further test whether this stimulation by
IGF-1 translated to growth-inhibitory effects of an anti-
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http://www.biomedcentral.com/1471-2407/13/170IGF-1R treatment, cell lines that were very sensitive
(Caki-2), moderately sensitive (786-O), and with low
sensitivity (ACHN) to IGF-1 treatment were incubated
with hR1 or Hex-hR1 in the presence of IGF-1. As
predicted by the stimulation experiment, both Caki-2 and
786-O demonstrated greater growth-inhibition by hR1
than did ACHN. Interestingly, Caki-2 also had the lowest
EGFR expression and ACHN one of the highest. Over-
expression of EGFR relative to normal kidney tissue has
been documented in patient RCC samples, and is thought
to be associated with the transformation of normal renal
tissue to malignancy [28]. Additionally, it is known that
both the IGF-1R and EGFR signaling pathways overlap,
and both make use of phosphatidylinositol-3 kinase
(PI3-K) and growth factor receptor bound protein 2
(Grb2) signaling pathways [29]. It is possible that in
cell lines with high EGFR surface expression relative
to IGF-1R, there may be less reliance on IGF-1 and
therefore less sensitivity to the stimulatory effects of
IGF-1. This was noted in hepatocellular carcinoma
lines, in which resistance to anti-IGF-1R treatment
was associated with increased signaling through EGFR
pathways, and that this resistance was overcome by
targeting both IGF-1R and EGFR [30]. It should be
noted that the rhabdomyosarcoma line, RH-30, has
the same surface expression of IGF-1R and EGFR
when examined by FACS (data not shown). This same
cell line was extremely sensitive to IGF-1, with growth-
stimulation more than 10-fold above cells grown in SFM.
We have demonstrated previously that this same cell line
was inhibited in cell migration assays by hR1 and could be
inhibited in its growth in vivo by both hR1 and Hex-hR1
[16]. These data suggest that EGFR expression levels
relative to IGF-1R also may be predictive of sensitivity of
RCC to monotherapy with an anti-IGF-1R antibody, and
that targeting both IGF-1R and EGFR would be a rational
approach in RCC.
While hR1 had modest effects at inhibiting cell growth,
Hex-hR1 had a greater effect on RCC, even on the resistant
ACHN cell line. This could be linked to the observation
that the hexavalent form of hR1 is more effective at mediat-
ing down-regulation of IGF-1R than the parental hR1.
Interestingly, MAB391, whose mechanisms of action in-
clude blocking IGF-1 from binding to IGF-1R as well as
down-regulation of IGF-1R [24], also was as effective as
Hex-hR1 at inhibiting cell growth. However, it is noted that
excess IGF-1 could reverse the IGF-1-mediated signaling
events blocked by MAB391 [24].
It has been observed that in cancer cells treated with
rapamycin, a negative feedback resulted in which p-AKT
levels increased in the cells [9,10]. Even under serum-free
conditions, when IGF-1 was added to cultures, rapamycin-
induced growth-inhibition was reversed and cell prolifera-
tion resumed at untreated levels [9]. One way this feedbackwas prevented was to treat cells with anti-IGF-1R anti-
bodies. When rapamycin treatment was combined with
anti-IGF-1R antibodies, an additive effect was achieved
[9,10]. Consistent with these findings and using a similar
system with RCC, cells treated with hR1 or Hex-hR1 plus
temsirolimus resulted in a synergistic growth-inhibitory
effect. A higher degree of growth-inhibition was achieved
with Hex-hR1 when combined with temsirolimus, in which
a greater than 130-fold improvement in the IC50 of tem-
siroliumus could be attained under these conditions. Such
a combination had previously been tested in vivo in which
hR1 and Hex-hR1 could significantly inhibit the growth of
a rhabdomyosarcoma when each was used with rapamycin
[16]. These combinations demonstrated more efficacy than
when any of the three agents were used alone, and provide
the rationale for such a combination in RCC.
As noted previously, efforts have also been made to
use cytokine therapy, in particular IFN-α, either alone or
with other treatment modalities to improve patient
outcomes [4-8]. However, one of the limitations of
systemic treatment with IFN-α is the adverse events
associated with the therapy [4,6-8]. We have previously
used the DNL method to incorporate four molecules of
IFN-α into veltuzumab, an anti-CD20 antibody currently in
clinical development, and shown that the resulting 20-2b
had greatly improved pharmacokinetics (PK) when com-
pared to pegylated IFN-α. We also showed that the tumor
targeting ability of 20-2b allowed for a low therapeutic dose
to be administered in lymphoma models [19], suggesting a
high therapeutic window for this immunocytokine. In the
present study, we explored the potential of 1R-2b, a new
DNL-based immunocytokine comprising hR1 IgG and four
IFN-α molecules, for use against RCC. 1R-2b had a specific
activity similar to peginterferon alfa-2b and superior to
peginterferon alfa-2a. When compared to IFN-α, 1R-2b
had the same ability to mediate phosphorylation of STAT1,
AKT and ERK1/2 at comparable concentrations. Additio-
nally, 1R-2b could inhibit the growth of two different RCC
lines in a similar manner as free IFN-α, indicating that the
IFN-α on 1R-2b is fully functional.
This growth-inhibitory effect by IFN-α has been
demonstrated previously in several human RCC lines,
including ACHN and 786-O [25]. One main mechanism
of action of IFN-α described in these RCC lines is the
up-regulation of the NEDD8 ultimate buster I (NUBI)
protein. There is a positive correlation in NUBI up-
regulation and cell growth inhibition in RCC [25].
NEDD8 is an ubiquitin-like molecule that covalently
binds to several different proteins including the VHL pro-
tein (pVHL) [31]. Normally, pVHL targets proteins in the
hypoxia-inducible factor (HIF)-α family for ubiquitination
and subsequent destruction. Defects in this gene, as in
many RCC tumors, result in the accumulation of HIF pro-
teins which in turn activate other growth factor genes that
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with RCC [32]. NEDD8 covalently binds to pVHL and
modifies it to allow for the proper assembly of the fibro-
nectin matrix, but failure to bind does not affect the ability
of pVHL to ubiquinate HIF [31]. In pVHL mutants, failure
of fibronectin assembly is associated with an undifferenti-
ated phenotype in RCC [33]. RCC cells treated with IFN-α
exhibit an up-regulation in cyclin E and p27 and the
down-regulation of NEDD8, which results in the accumu-
lation of cells in S-phase and induction of apoptosis. It is
thought that the NEDD8 conjugation system plays a role
in the ubiquitination of p27 and cyclin E such that NUBI-
mediated degradation of NEDD8 induces growth arrest
and apoptosis of RCC [25]. When ACHN and 786-O were
exposed to 1R-2b, there was a greater than 2-fold increase
in NUB1 expression. However, while rhIFN-α2a had a
similar effect in 786–0, in ACHN 1R-2b mediated a higher
increase in expression levels than what was observed with
rhIFN-α2a. Likewise, similar to what was reported previ-
ously [25], a correlation between NUB1 expression and
growth inhibition was observed with 1R-2b in ACHN, in
that 1R-2b resulted in a significantly greater degree of
growth inhibition when compared to rhIFN-α2a.
Inhibition of mTOR likewise affects the cell cycle, with a
down-regulation of cyclin D and the inability to progress
from G1 to S-phase [5]. There is also evidence that Type I
IFNs, such as IFN-α, may have parallel AKT/mTOR signal-
ing pathways that promote growth-inhibitory signals [34],
and that by blocking mTOR it may antagonize the effect of
IFN-α treatment. To determine if this action by
IFN-α would have an added or antagonistic effect when
combined with the mTOR inhibitor, temsirolimus, RCC
cells were incubated with both temsirolimus and 1R-2b.
This combination proved to be very potent, with a
synergistic effect observed at a 1R-2b concentration as
low as 2.6 nM. These data indicate that even if
IFN-α used the mTOR pathway in parallel to inhibit cell
growth in RCC, it must play only a minor role, because
blocking such activity by temsirolimus did not blunt the
effect of 1R-2b, and actually worked in synergy with it to
inhibit cell growth. Given the improved PK profile of the
MAb-2b construct in comparison to PEGylated-IFN-α
[19] and its added ability to potentially target the IFN to
the tumor, 1R-2b should have the ability to be active
clinically at doses substantially lower than currently
administered IFN-α. Moreover, this synergistic effect,
when combined with temsirolimus, provides the rationale
for clinical use of 1R-2b to mitigate the dose-limiting
toxicity associated with systemic administration of
IFN-α when used in concert with RTK inhibitors.
In summary, monotherapy with mTOR inhibitors has
met with only modest effects clinically due mainly to the
ability of some cancer cells to use signaling pathways up-
stream and parallel to mTOR to overcome this inhibition[35]. Two such upstream pathways originate with IGF-1R,
which will activate Akt and Ras when bound by its ligand
[36]. It has been demonstrated that depletion of RCC cells
of IGF-1R with small interfering RNA (siRNA) enhanced
the sensitivity of these cells to the inhibitory effects of
rapamycin [37]. Here we show that this same effect in
RCC can be accomplished with hR1 and Hex-hR1. We
believe that by using hR1 or Hex-hR1 to down-regulate
IGF-1R in combination with temsirolimus, multiple prolif-
eration pathways are blocked, leaving RCC little chance to
bypass them and escape death. In a similar fashion, 1R-2b
may affect a cell’s ability to progress through a normal cell
cycle by the accumulation of cyclin E and p27, resulting in
arrest at the S-phase [25]. Inhibition of mTOR also will
block a normal progression through the cell cycle by the
down-regulation of cyclin D [5]. Again, by combining 1R-
2b with temsirolimus, two different pathways that lead to
normal progression through the cell cycle may be affected,
resulting in cell cycle arrest and inhibition of cell growth.Conclusions
We have demonstrated that by targeting multiple cell
proliferation pathways in RCC simultaneously, a potent
growth-inhibitory effect is observed in vitro. In particu-
lar, by using a humanized anti-IGF-1R antibody and its
hexavalent form to mediate IGF-1R down-regulation in
concert with the mTOR inhibitor, temsirolimus, cell
growth is effectively blocked. Additionally, using our DNL-
platform to make an anti-IGF-1R/IFN-α immunocytokine,
a very potent therapeutic was created that also synergizes
with temsirolimus to inhibit RCC cell growth. Finally, since
DNL lends itself to design many combinations of different
antibodies, possibly more potent bispecific antibodies can
be generated from hR1 and anti-EGFR or -VEGF antibodies
to target multiple growth pathways in RCC. Given the
potent activity these anti-IGF-1R agents demonstrate
against RCC when combined with temsirolimus, such a
combination may prove to be beneficial clinically in the
management of RCC.
Competing interests
All authors have employment and stock or stock options with
Immunomedics, Inc.
Authors’ contributions
Conceived and designed the experiments: TMC, DMG, CHC. Performed the
experiments: PT, RA. Analyzed the data: TMC, CHC, PT, RA. Contributed
reagents/materials: CHC. Wrote and revised the paper: TMC, DMG, CHC.
Provided financial support: DMG. All authors read and approved the final
manuscript.
Acknowledgements
The study was supported in part by a SBIR grant from the NIH (1R
43CA150742-01; PI: TMC). We thank Anju Nair and Maria Zalath for technical
assistance, and Diana Chereches and John Kopinski for the construction of
the DNL molecules used in these studies.
Cardillo et al. BMC Cancer 2013, 13:170 Page 14 of 14
http://www.biomedcentral.com/1471-2407/13/170Author details
1Immunomedics, Inc, 300 American Rd, Morris Plains, NJ 07950, USA. 2IBC
Pharmaceuticals, Inc, 300 American Rd, Morris Plains, NJ 07950, USA. 3Center
of Molecular Medicine and Immunology, Garden State Cancer Center, 300
American Rd, Morris Plains, NJ 07950, USA.
Received: 17 October 2012 Accepted: 19 March 2013
Published: 1 April 2013
References
1. American Cancer Society: Cancer Facts and Figures 2012. Atlanta: American
Cancer Society; 2012.
2. Fisher R, Gore M, Larkin J: Current and future systemic treatments for
renal cell carcinoma. Semin Cancer Biol 2013, 23:38–45.
3. Aschenbrenner DS: New drug approved for advanced renal cell
carcinoma. Am J Nurs 2012, 112:22–23.
4. Gollob JA, Rathmell WK, Richmond TM, Marino CB, Miller EK, Grigson G,
Watkins C, Gu L, Peterson BL, Wright JJ: Phase II trial of sorafenib plus
interferon alfa-2b as first- or second-line therapy in patients with
metastatic renal cell cancer. J Clin Oncol 2007, 25:3288–3295.
5. Kapoor A, Figlin RA: Targeted inhibition of mammalian target of
rapamycin for the treatment of advanced renal cell carcinoma.
Cancer 2009, 115:3618–3630.
6. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN,
Picus J, Czaykowski P, Dutcher J, Small EJ: Phase III trial of bevacizumab
plus interferon alfa versus interferon alfa monotherapy in patients with
metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol
2010, 28:2137–2143.
7. Motzer RJ, Rakhit A, Ginsberg M, Rittweger K, Vuky J, Yu R, Fettner S,
Hooftman L: Phase I trial of 40-kd branched pegylated interferon alfa-2a
for patients with advanced renal cell carcinoma. J Clin Oncol 2001,
19:1312–1319.
8. Motzer RJ, Rakhit A, Thompson J, Gurney H, Selby P, Figlin R, Negrier S,
Ernst S, Siebels M, Ginsberg M, Rittweger K, Hooftman L: Phase II trial of
branched peginterferon-α2a (40 kDa) for patients with advanced renal
cell carcinoma. Ann Oncol 2002, 13:1799–1805.
9. O’Reilly KE, Rojo F, She Q-B, Solit D, Mills GB, Smith D, Lane H, Hofmann F,
Hicklin DJ, Ludwig DL, Baselga J, Rosen N: mTOR inhibition induces
upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res
2006, 66:1500–1508.
10. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ: Rapamycin induces
feedback activation of Akt signaling through an IGF-1R-dependent
mechanism. Oncogene 2007, 26:1932–1940.
11. Jungwirth A, Schally AV, Pinski J, Groot K, Armatis P, Halmos G: Growth
hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo
proliferation of Caki-I renal adenocarcinoma. Proc Natl Acad Sci USA 1997,
94:5810–5813.
12. Schips L, Ziegeuner R, Ratschek M, Pehak P, Rüschoff J, Langner C: Analysis
of insulin-like growth factors and insulin-like growth factor I receptor
expression in renal cell carcinoma. Am J Clin Pathol 2004,
122:931–937.
13. Parker AS, Chebille JC, Blute ML, Igel T, Lohse CM, Cerhan JR: Pathologic T1
clear renal cell carcinoma: insulin-like growth factor-I receptor
expression and disease-specific survival. Cancer 2004, 100:2577–2582.
14. Kidney Cancer Association. http://www.kidneycancer.org/knowledge/learn/
about-kidney-cancer.
15. Datta K, Nambudripad R, Pal S, Zhou M, Cohen HT, Mukhopadhyay D:
Inhibition of insulin-like growth factor-I-mediated cell signaling by the
von Hippel-Lindau gene product in renal cancer. J Biol Chem 2000,
275:20700–20706.
16. Chang C-H, Wang Y, Trisal P, Li R, Rossi DL, Nair A, Gupta P, Losman M,
Cardillo TM, Rossi EA, Goldenberg DM: Evaluation of a novel hexavalent
humanized anti-IGF-1R antibody and its bivalent parental IgG in diverse
cancer cell lines. PLoS One 2012, 7:e44235.
17. Chang CH, Rossi EA, Goldenberg DM: The dock and lock method: a novel
platform technology for building multivalent, multifunctional structures
of defined composition with retained bioactivity. Clin Cancer Res 2007,
13(Suppl 19):5586s–5591s.
18. Rossi EA, Goldenberg DM, Chang C-H: The Dock-and-Lock method
combines recombinant engineering with site-specific covalent conjugation
to generate multifunctional structures. Bioconjug Chem 2012, 23:309–323.19. Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang C-H: CD20-targeted
tetrameric interferon-α, a novel and potent immunocytokine for the
therapy of B-cell lymphomas. Blood 2009, 114:3864–3871.
20. Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: the
combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme
Regul 1984, 22:27–55.
21. Reynolds CP, Maurer BJ: Evaluating response to antineoplastic drug
combinations in tissue culture models. Methods Mol Med 2005, 110:173–183.
22. Kim JG, Kang MJ, Yoon Y-K, Kim H-P, Park J, Song S-H, Han S-W, Park J-W,
Kang GH, Kang KW, Oh DY, Im S-A, Bang Y-J, Yi EC, Kim T-Y:
Heterodimerization of glycosylated insulin-like growth factor-1 receptors
and insulin receptors in cancer cells sensitive to anti-IGF1R antibody.
PLoS One 2012, 7:e33322.
23. Zha J, O’Brien C, Savage H, Huw L-Y, Zhong F, Berry L, Lewis Phillips GD,
Luis E, Cavet G, Hu X, Amler LC, Lackner MR: Molecular predictors of
response to a humanized anti-insulin-like growth factor-I receptor
monoclonal antibody in breast and colorectal cancer. Mol Cancer Ther
2009, 8:2110–2121.
24. Hailey J, Maxwell E, Koukouras K, Bishop WR, Pachter JA, Wang Y:
Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit
receptor function and induce receptor degradation in tumor cells.
Mol Cancer Res 2002, 1:1349–1353.
25. Hosono T, Tanaka T, Tanji K, Nakatani T, Kamitani T: NUBI, an interferon-
inducible protein, mediates anti-proliferative actions and apoptosis in
renal cell carcinoma cells through cell-cycle regulation. Br J Cancer 2010,
102:873–882.
26. Bukowski R, Ernstoff MS, Gore ME, Nemunaitis JJ, Amato R, Gupta SK,
Tendler CL: Pegylated interferon alfa-2b treatment for patients with solid
tumors: a phase I/II study. J Clin Oncol 2002, 20:3841–3849.
27. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S,
Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA,
Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA:
Overall survival and updated results for sunitinib compared with
interferon alfa in patients with metastatic renal cell carcinoma. J Clin
Oncol 2009, 27:3584–3590.
28. Sargent ER, Gomella LG, Belldgrun A, Linehan WM, Kasid A: Epidermal
growth factor receptor gene expression in normal and human kidney
and renal cell carcinoma. J Urol 1989, 142:1364–1368.
29. van der Veeken J, Oliveira S, Schiffelers RM, Storm G, Roovers RC, van
Bergen en Henegouwen PMP: Crosstalk between epidermal growth factor
receptor- and insulin-like growth factor-1 receptor signaling:
Implications for cancer therapy. Curr Cancer Drug Targets 2009, 9:748–760.
30. Desbois-Mouthon C, Baron A, Blivet-Van Eggeloël MJ, Fartoux L, Venot C, Bladt
F, Housset C, Rosmorduc O: Insulin-like growth factor-1 receptor inhibition
induces a resistance mechanism via the epidermal growth factor receptor/
HER3/AKT signaling pathway: rational basis for the cotargeting insulin-like
growth factor-1 receptor and epidermal growth factor receptor in
hepatocellular carcinoma. Clin Cancer Res 2009, 15:5445–5456.
31. Stickle NH, Chung J, Klco JM, Hill RP, Kaelin WG Jr, Ohh M: pVHL
modification by NEDD8 is required for fibronectin matrix assembly and
suppression of tumor development. Mol Cell Biology 2004, 24:3251–3261.
32. Kaelin WG Jr: The von Hippel-Lindau tumor suppressor gene and kidney
cancer. Clin Cancer Res 2004, 10(Suppl 18 Pt 2):6290s–6295s.
33. Lieubaeu-Teillet B, Rak J, Jothy S, Iliopoulos O, Kaelin W, Kerbel R: von
Hippel-Lindau gene-mediated growth suppression and induction of
differentiation in renal cell carcinoma cells grown as multicullular tumor
spheroids. Cancer Res 1998, 58:4957–4962.
34. Kroczynska B, Kaur S, Platanias LC: Growth suppressive cytokines and the
AKT/mTOR pathway. Cytokine 2009, 48:138–143.
35. Meric-Bernstam F, Gonzalez-Angulo AM: Targeting the mTOR signaling
network for cancer therapy. J Clin Oncol 2009, 27:2278–2287.
36. Zha J, Lackner MR: Targeting the insulin-like growth factor receptor-1R
pathway for cancer therapy. Clin Cancer Res 2010, 16:2512–2517.
37. Yuen JSP, Akkaya E, Wang Y, Takiguchi M, Peak S, Sullivan M, Protheroe AS,
Macaulay VM: Validation of the type 1 insulin-like growth factor receptor as
a therapeutic target in renal cancer. Mol Cancer Ther 2009, 8:1448–1459.
doi:10.1186/1471-2407-13-170
Cite this article as: Cardillo et al.: Targeting both IGF-1R and mTOR
synergistically inhibits growth of renal cell carcinoma in vitro. BMC
Cancer 2013 13:170.
